AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

SYNAIRGEN PLC

Report Publication Announcement Apr 9, 2013

7941_rns_2013-04-09_403ff568-3d47-4c8a-8a75-d6b8d4d69b18.html

Report Publication Announcement

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 9500B

Synairgen plc

09 April 2013

Press release

Synairgen plc

('Synairgen' or the 'Company')

Notice of Report and Accounts

Southampton, UK - 9 April 2013: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company with a focus on viral defence of the lungs, announces that the Company's Report and Accounts for the year ended 31 December 2012 has been posted to shareholders. A copy of the report and accounts can be found on the Company's website: www.synairgen.com.

-Ends-

For further information, please contact:

Synairgen plc                                                                          Tel: + 44 (0) 23 8051 2800

Richard Marsden, Chief Executive Officer

John Ward, Finance Director

FinnCap                                                                                  Tel: + 44 (0) 20 7220 0500

Geoff Nash, Christopher Raggett (Corporate Finance)

Stephen Norcross, Simon Starr (Corporate Broking)

Newgate Threadneedle                                                                       Tel: + 44 (0) 20 7653 9850

Graham Herring

Josh Royston

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCZMGGDKLKGFZM

Talk to a Data Expert

Have a question? We'll get back to you promptly.